Abbvie pulls plug on Swedish R&D partnership

Swedish biotech firm Bioarctic expresses its disappointment over Abbvie’s decision to terminate a collaborative partnership on potential Parkinson’s treatments.

Photo: Abbvie / PR

US-based Abbvie has decided to end a collaboration with Swedish biotech firm Bioartic on the latter’s portfolio of alpha-synuclein antibodies, the company has announced in a press release.

The portfolio targeted Parkinson’s diseases and other indications, and included monoclonal antibody candidate ABBV-0805, the collaboration’s lead asset.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs